Vomifoliol
Based on 1 Customer Validation
Vomifoliol, a compound related to abscisie acid (ABA), has a modified 2,4-pentadiene side chain and has activity equal to that displayed by ABA. Vomifoliol exhibits antiacetylcholinesterase activity and displays moderate antileishmanial activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97.0%
- CAS No.: 23526-45-6
- Formule: C13H20O3
- Masse moléculaire:224.30
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Voir tous les produits spécifiques à Isoform Endogenous Metabolite
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>10 μM
Compound: 13
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| HeLa | IC50 |
12.3 μM
Compound: 4
|
Inhibition of NF-kappaB activity in human HeLa cells by SEAP reporter assay
Inhibition of NF-kappaB activity in human HeLa cells by SEAP reporter assay
|
[PMID: 20469887] |
| Hep 3B2 | IC50 |
15.8 μM
Compound: 4
|
Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis
Inhibition of hypoxia-induced HIF1alpha protein accumulation in human Hep3B cells treated for 30 mins measured after 12 hrs by Western blot analysis
|
[PMID: 20469887] |
| Hep 3B2 | IC50 |
26.2 μM
Compound: 4
|
Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA
Inhibition of hypoxia-induced VEGF protein secretion in human Hep3B cells after 16 hrs by ELISA
|
[PMID: 20469887] |
| HT-29 | IC50 |
>10 μM
Compound: S10
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| HT-29 | IC50 |
>10 μM
Compound: S10
|
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
|
[PMID: 30057155] |
| Jurkat | IC50 |
20.17 μM
Compound: Vom
|
Cytotoxicity against human Jurkat cells assessed as inhibition of PMA/ionomycin-induced proliferation measured after 48 hrs by MTT assay
Cytotoxicity against human Jurkat cells assessed as inhibition of PMA/ionomycin-induced proliferation measured after 48 hrs by MTT assay
|
[PMID: 34216746] |
| KB | IC50 |
>10 μM
Compound: 13
|
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| MCF7 | IC50 |
>10 μM
Compound: 13
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| MDA-MB-231 | IC50 |
>10 μM
Compound: 13
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 32946697] |
| MDA-MB-231 | IC50 |
>10 μM
Compound: S10
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| MDA-MB-435 | IC50 |
>10 μM
Compound: S10
|
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-435 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| N9 | IC50 |
43.49 μM
Compound: 26
|
Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
|
[PMID: 28073678] |
| OVCAR-3 | IC50 |
>10 μM
Compound: S10
|
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human OVCAR3 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| Splenocyte | IC50 |
18.65 μM
Compound: Vom
|
Cytotoxicity against mouse splenocytes assessed as cell survival in presence of ConA measured after 44 hrs by CCK-8 assay
Cytotoxicity against mouse splenocytes assessed as cell survival in presence of ConA measured after 44 hrs by CCK-8 assay
|
[PMID: 34216746] |
Chemical Information
-
CAS No. 23526-45-6
-
Appearance Solid
-
Masse moléculaire 224.30
-
Formule C13H20O3
-
Color White to off-white
-
SMILES
O=C1C=C(C)[C@@](/C=C/[C@H](O)C)(O)C(C)(C)C1
-
Structure Classification
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvant et solubilité
DMSO : 50 mg/mL (222.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.25 mg/mL (5.57 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1.25 mg/mL (5.57 mM); Clear solution
This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (272 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.4583 mL | 22.2916 mL | 44.5831 mL | 111.4579 mL |
| 5 mM | 0.8917 mL | 4.4583 mL | 8.9166 mL | 22.2916 mL | |
| 10 mM | 0.4458 mL | 2.2292 mL | 4.4583 mL | 11.1458 mL | |
| 15 mM | 0.2972 mL | 1.4861 mL | 2.9722 mL | 7.4305 mL | |
| 20 mM | 0.2229 mL | 1.1146 mL | 2.2292 mL | 5.5729 mL | |
| 25 mM | 0.1783 mL | 0.8917 mL | 1.7833 mL | 4.4583 mL | |
| 30 mM | 0.1486 mL | 0.7431 mL | 1.4861 mL | 3.7153 mL | |
| 40 mM | 0.1115 mL | 0.5573 mL | 1.1146 mL | 2.7864 mL | |
| 50 mM | 0.0892 mL | 0.4458 mL | 0.8917 mL | 2.2292 mL | |
| 60 mM | 0.0743 mL | 0.3715 mL | 0.7431 mL | 1.8576 mL | |
| 80 mM | 0.0557 mL | 0.2786 mL | 0.5573 mL | 1.3932 mL | |
| 100 mM | 0.0446 mL | 0.2229 mL | 0.4458 mL | 1.1146 mL |